Michael Weaver, Author at BioLife Solutions

Journal Articles Citing CryoStor CS10^® Recently Added to BioLife Solutions’ Evidence Library

September 3, 2020

Multiple Uses for CryoStor in Cell Manufacturing Journal articles recently added to BioLife Solutions’ Evidence Library illustrate several stages during the cell manufacturing process for which CryoStor CS10® cryopreservation solution is applicable. The three articles that follow include several different cell types cryopreserved in CryoStor CS10. An expanded list of cell types biopreserved in BioLife…

Cellular Therapies for COVID-19 Highlighted During ISCT Paris 2020 VIRTUAL

June 11, 2020June 12, 2020

Michael Weaver

The global impact of COVID-19 on our lives has been profound at virtually every level. Personally, professionally, politically, and economically, the pandemic impacts our lives, our relationships, and how we conduct business. We begin and end the day with the latest news on SARS-CoV-2, and up-to-the-minute COVID-19 data. In between, we must surmount any number…

BioLife Solutions Among The Americas’ Fastest Growing Companies!

April 24, 2020October 19, 2021

Michael Weaver

The Financial Times identified companies across the Americas that achieved the highest CAGRs in revenue between 2015 – 2018 The FT employed research company, Statista, to survey growth companies across North, Central, and South Americas to list and rank the top 500 participating, independent companies in terms of compound annual growth rate (CAGR) during the…

Journal Articles Citing Cryopreservation Component Recently Added to BioLife Solutions’ Evidence Library

March 19, 2020

Michael Weaver

Cryopreservation adds flexibility to timelines when working with cells. In the case of cellular therapies, that can mean initial flexibility to schedule patient cell collection, transport cells to the manufacturing facility and initiate manufacturing. Cryopreservation of the final cell therapy product adds flexibility to be able to schedule the return of cells to the patient…

Joining Forces!

August 13, 2019August 13, 2019

Michael Weaver

BioLife Solutions issued a press release August 8, 2019, announcing the execution of a share exchange agreement to purchase the remaining 56% of shares of SAVSU Technologies that BioLife did not previously own. BioLife’s relationship with Savsu spans six years, during the development and growth of the evo® Cold Chain 2.0™ system, encompassing evo® hardware…

Could not attend? BioLife Solutions’ Posters Presented During ISCT 2019 International Meeting in Melbourne

July 2, 2019

Michael Weaver

Posters presenting data for T-cells cryopreserved in CryoStor® cryopreservation solution, authored by BioLife Solutions’ Alireza Abazari, Ph.D., Scientific Applications Director and Aby J. Mathew, Ph.D., Senior Vice President & Chief Technology Officer, were featured during the International Society for Cell & Gene Therapy meeting in Melbourne, Australia, May 29 – June 1, 2019. View the…

TrakCel and Quick Partnering Solution

February 27, 2019October 19, 2021

Michael Weaver

According to data provided by the Alliance for Regenerative Medicine, there are nearly 900 companies responsible for more than 1000 industry-sponsored clinical trials within regenerative medicine utilizing advanced therapeutics including cell, gene, and tissue engineered products. Maintaining oversight on these precious therapies, literally vein-to-vein, encompassing a multitude of stakeholders, lengthy timelines, across countries and continents…

BioPreservation Blog 1/30/2019

January 30, 2019October 19, 2021

Michael Weaver

Disease models facilitate understanding the pathogenesis of disease, identification and development of potential interventions and evaluation of new treatments. BioLife Solutions maintains an online, searchable, Evidence Library that contains over 365 articles, abstracts and posters citing Biopreservation efficacy of CryoStor® and HypoThermosol®. Recently added to the Evidence Library, the journal article authored by Xinyue Bai…

BioPreservation Blog 12/20/18

December 20, 2018October 19, 2021

Michael Weaver

One of the benefits of cryopreserving cells is the flexibility in scheduling for later use that freezing provides. Determining the optimal solution for cryopreservation that consistently results in post-thaw recovery of the greatest number of highly viable, functional cells is crucial. The article by Sara S. Parker et al. published in eNeuro and recently added…

MSCs Featured in Recent Journal Articles Adds to BioLife’s Growing Evidence Library

November 9, 2018November 9, 2018

Michael Weaver

Mesenchymal Stem Cells have been the cell type of interest for the following articles recently entered into BioLife’s growing Evidence library. 1. Sutton, M. T., Kaur, S., Brown, K. S., Skiles, M. L., Folz, M. A., Caplan, A. I. and Bonfield, T. L.. (2018). Anti-Inflammatory Therapeutic Development and Optimization of Umbilical Cord Tissue Derived Mesenchymal…

Cart

Author: Michael Weaver

Journal Articles Citing CryoStor CS10^® Recently Added to BioLife Solutions’ Evidence Library

Cellular Therapies for COVID-19 Highlighted During ISCT Paris 2020 VIRTUAL

BioLife Solutions Among The Americas’ Fastest Growing Companies!

Journal Articles Citing Cryopreservation Component Recently Added to BioLife Solutions’ Evidence Library

Joining Forces!

Could not attend? BioLife Solutions’ Posters Presented During ISCT 2019 International Meeting in Melbourne

TrakCel and Quick Partnering Solution

BioPreservation Blog 1/30/2019

BioPreservation Blog 12/20/18

MSCs Featured in Recent Journal Articles Adds to BioLife’s Growing Evidence Library